Do you anticipate a paradigm shift in first line treatment of multiple myeloma from RVD to immune therapy with CAR-T/bispecifics?  

A great question that is no doubt being discussed not just by doctors & patients but also by investors, insurance companies, and more. It is certainly possible to shift paradigms in myeloma - I'd even argue, for example, that the induction strategy at most US centers now is Dara-VRd and not VRd ...

I agree with @Rahul Banerjee that investigators and pharmaceutical companies are engaged in frontline trials that propose all sorts of cell therapy and bispecific regimens for every type of untreated myeloma patient, from a fit newly diagnosed patient to a t(11;14) plasma cell leukemic. Getting...